Table 3.

Risk of prostate cancer recurrence/progression by SLCO2B1 and SLCO1B3 SNP genotypes in a population-based prostate cancer cohort^a

	SNP	Genotype	Recurrence/progression		HR (95% CI)^b
			No (n = 326)	Yes (n = 143)
SLCO2B1	rs12422149	GG	254 (69.2)	113 (30.8)	1.00 (referent)
		GA + AA	47 (66.2)	24 (33.8)	1.09 (0.68–1.75)
SLCO2B1	rs949069	GG	216 (69.5)	95 (30.6)	1.00 (referent)
		GA + AA	87 (66.4)	44 (33.6)	1.19 (0.82–1.73)
SLCO2B1	rs2712819	AA	194 (70.6)	81 (29.5)	1.00 (referent)
		AG + GG	109 (65.7)	57 (34.3)	1.35 (0.95–1.91)
SLCO2B1	rs2851069	CC	116 (70.3)	49 (29.7)	1.00 (referent)
		CT + TT	184 (66.9)	91 (33.1)	1.31 (0.92–1.89)
SLCO2B1	rs7947726	GG	259 (69.1)	116 (30.9)	1.00 (referent)
		AG + AA	44 (67.7)	21 (32.3)	1.21 (0.75–1.95)
SLCO1B3	rs4149117	GG	221 (68.0)	104 (32.0)	1.00 (referent)
		GT + TT	84 (70.0)	36 (30.0)	0.85 (0.57–1.26)
SLCO1B3	rs3829311	GG	206 (68.0)	97 (32.0)	1.00 (referent)
		GA + AA	98 (69.5)	43 (30.5)	0.83 (0.57–1.21)
SLCO1B3	rs4762803	CC	239 (68.3)	111 (31.7)	1.00 (referent)
		CG + GG	66 (70.2)	28 (29.8)	0.86 (0.56–1.32)

↵^aRecurrence/progression data available for 469 cases, variable number of cases due to failed genotyping.
↵^bAdjusted for age, PSA at diagnosis, Gleason score, tumor stage, primary treatment, BMI, and smoking status.